Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Omar S Al-Odat

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Cytokine|May 5, 2024
Is it possible to treat melanoma by intercepting the CXCR4/CXCL12 pathway?Miriam Motlak, Meghna Mathews, Omar S Al-Odat, et al.
Cancers|July 13, 2024
Discovering Potential in Non-Cancer Medications: A Promising Breakthrough for Multiple Myeloma PatientsOmar S Al-Odat, Emily Nelson, Tulin Budak-Alpdogan, et al.
Heliyon|July 18, 2024
Pathways to therapy resistance: The sheltering effect of the bone marrow microenvironment to multiple myeloma cellsKuntal Bhowmick, Max von Suskil, Omar S Al-Odat, et al.
International Journal of Molecular Sciences|January 8, 2023
Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple MyelomaOmar S Al-Odat, Daniel A Guirguis, Nicole K Schmalbach, et al.
Frontiers in Pharmacology|October 16, 2024
KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosisOmar S Al-Odat, Weam Othman Elbezanti, Krishne Gowda, et al.
Biorxiv : the Preprint Server for Biology|January 16, 2026
Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated DegradationLin Zhang, Arnold Bolomsky, Omar S Al-Odat, et al.
International Journal of Molecular Sciences|June 2, 2021
Bruton's Tyrosine Kinase Targeting in Multiple MyelomaMax Von Suskil, Kazi Nasrin Sultana, Weam Othman Elbezanti, et al.
Frontiers in Pharmacology|September 26, 2022
Development of a novel Bruton's tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cellsWeam Othman Elbezanti, Omar S Al-Odat, Robert Chitren, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Cytokine|May 5, 2024
Is it possible to treat melanoma by intercepting the CXCR4/CXCL12 pathway?Miriam Motlak, Meghna Mathews, Omar S Al-Odat, et al.
Cancers|July 13, 2024
Discovering Potential in Non-Cancer Medications: A Promising Breakthrough for Multiple Myeloma PatientsOmar S Al-Odat, Emily Nelson, Tulin Budak-Alpdogan, et al.
Heliyon|July 18, 2024
Pathways to therapy resistance: The sheltering effect of the bone marrow microenvironment to multiple myeloma cellsKuntal Bhowmick, Max von Suskil, Omar S Al-Odat, et al.
International Journal of Molecular Sciences|January 8, 2023
Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple MyelomaOmar S Al-Odat, Daniel A Guirguis, Nicole K Schmalbach, et al.
Frontiers in Pharmacology|October 16, 2024
KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosisOmar S Al-Odat, Weam Othman Elbezanti, Krishne Gowda, et al.
Biorxiv : the Preprint Server for Biology|January 16, 2026
Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated DegradationLin Zhang, Arnold Bolomsky, Omar S Al-Odat, et al.
International Journal of Molecular Sciences|June 2, 2021
Bruton's Tyrosine Kinase Targeting in Multiple MyelomaMax Von Suskil, Kazi Nasrin Sultana, Weam Othman Elbezanti, et al.
Frontiers in Pharmacology|September 26, 2022
Development of a novel Bruton's tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cellsWeam Othman Elbezanti, Omar S Al-Odat, Robert Chitren, et al.
Pageof 1